<SEC-DOCUMENT>0001390478-22-000021.txt : 20220811
<SEC-HEADER>0001390478-22-000021.hdr.sgml : 20220811
<ACCEPTANCE-DATETIME>20220811161453
ACCESSION NUMBER:		0001390478-22-000021
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20220811
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220811
DATE AS OF CHANGE:		20220811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SELLAS Life Sciences Group, Inc.
		CENTRAL INDEX KEY:			0001390478
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33958
		FILM NUMBER:		221156039

	BUSINESS ADDRESS:	
		STREET 1:		7 TIMES SQUARE
		STREET 2:		SUITE 2503
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		6462005278

	MAIL ADDRESS:	
		STREET 1:		7 TIMES SQUARE
		STREET 2:		SUITE 2503
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Galena Biopharma, Inc.
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RXi Pharmaceuticals Corp
		DATE OF NAME CHANGE:	20110926

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GALENA BIOPHARMA, INC.
		DATE OF NAME CHANGE:	20110922
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>sls-20220811.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:639b7971-57df-4e97-8611-e0137314c59d,g:c9bd04e0-8b28-4fc7-bb83-d7660659717a,d:597cd532e7964a7b8b77b2448c4d77fe--><html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sls-20220811</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV80L2ZyYWc6NzU4ZGY2YzAyYWNmNDY4NjkzY2Y5NDFlMzE4MWJiMmQvdGFibGU6MDI2NzE3NGYyMDdkNDU3MmE0MjZhOTRmMzEwZjQxYjYvdGFibGVyYW5nZTowMjY3MTc0ZjIwN2Q0NTcyYTQyNmE5NGYzMTBmNDFiNl8xLTEtMS0xLTQyMzgz_6ce6e8c7-dc6d-4fc1-a7df-9717be746850">0001390478</ix:nonNumeric><ix:nonNumeric contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV80L2ZyYWc6NzU4ZGY2YzAyYWNmNDY4NjkzY2Y5NDFlMzE4MWJiMmQvdGFibGU6MDI2NzE3NGYyMDdkNDU3MmE0MjZhOTRmMzEwZjQxYjYvdGFibGVyYW5nZTowMjY3MTc0ZjIwN2Q0NTcyYTQyNmE5NGYzMTBmNDFiNl8yLTEtMS0xLTQyMzgz_75df2606-4940-48cf-af78-fc89eb45aca5">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sls-20220811.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001390478</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-11</xbrli:startDate><xbrli:endDate>2022-08-11</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i597cd532e7964a7b8b77b2448c4d77fe_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">UNITED STATES <br/>SECURITIES AND EXCHANGE COMMISSION  <br/>WASHINGTON, D.C. 20549 </span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGV4dHJlZ2lvbjo4Zjk3MDk4MGE0MTU0NzlmYTQ3M2YzOWIxM2JhNzgxMF8yODE3_78016580-b4c1-4b30-b874-40da58f7b07e">8-K</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">CURRENT REPORT<br/>PURSUANT TO SECTION 13 OR 15(d) OF THE <br/>SECURITIES EXCHANGE ACT OF 1934 </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported):</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGV4dHJlZ2lvbjo4Zjk3MDk4MGE0MTU0NzlmYTQ3M2YzOWIxM2JhNzgxMF8yMzQ_fe947ced-8c86-4f48-8a07-883ffca45ec8">August 11, 2022</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:10.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:160.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGV4dHJlZ2lvbjo4Zjk3MDk4MGE0MTU0NzlmYTQ3M2YzOWIxM2JhNzgxMF8yODEy_3692c0bb-1032-4dfd-9304-ad1c1050c9ba">SELLAS Life Sciences Group, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.527%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6MjMxYWU4N2EyYzAwNDZmNGIyYTUwOTI1N2Y0OTYzN2YvdGFibGVyYW5nZToyMzFhZTg3YTJjMDA0NmY0YjJhNTA5MjU3ZjQ5NjM3Zl8wLTAtMS0xLTQyMzgz_e2ee1c96-bfbb-4613-9cd5-f400c8247d3d">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6MjMxYWU4N2EyYzAwNDZmNGIyYTUwOTI1N2Y0OTYzN2YvdGFibGVyYW5nZToyMzFhZTg3YTJjMDA0NmY0YjJhNTA5MjU3ZjQ5NjM3Zl8wLTItMS0xLTQyMzgz_1562a388-d3eb-4613-bd84-05885c042741">001-33958</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6MjMxYWU4N2EyYzAwNDZmNGIyYTUwOTI1N2Y0OTYzN2YvdGFibGVyYW5nZToyMzFhZTg3YTJjMDA0NmY0YjJhNTA5MjU3ZjQ5NjM3Zl8wLTQtMS0xLTQyMzgz_9d00745a-2f0e-442c-8927-ac1b3a165101">20-8099512</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">File Number)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6MjMxYWU4N2EyYzAwNDZmNGIyYTUwOTI1N2Y0OTYzN2YvdGFibGVyYW5nZToyMzFhZTg3YTJjMDA0NmY0YjJhNTA5MjU3ZjQ5NjM3Zl8zLTItMS0xLTQyMzgzL3RleHRyZWdpb246NjA1NGFiNTdiYmIxNGRhOTgwZDFjYjMxNmY0ZTkxZDBfNQ_1d958634-68dd-4059-a0d4-44856569ee4f">7 Times Square</ix:nonNumeric>, <ix:nonNumeric contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6MjMxYWU4N2EyYzAwNDZmNGIyYTUwOTI1N2Y0OTYzN2YvdGFibGVyYW5nZToyMzFhZTg3YTJjMDA0NmY0YjJhNTA5MjU3ZjQ5NjM3Zl8zLTItMS0xLTQyMzgzL3RleHRyZWdpb246NjA1NGFiNTdiYmIxNGRhOTgwZDFjYjMxNmY0ZTkxZDBfOQ_5d88de44-e2f8-43f8-a38a-1a26a5b8c1ba">Suite 2503</ix:nonNumeric></span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6MjMxYWU4N2EyYzAwNDZmNGIyYTUwOTI1N2Y0OTYzN2YvdGFibGVyYW5nZToyMzFhZTg3YTJjMDA0NmY0YjJhNTA5MjU3ZjQ5NjM3Zl8zLTItMS0xLTQyMzgzL3RleHRyZWdpb246NjA1NGFiNTdiYmIxNGRhOTgwZDFjYjMxNmY0ZTkxZDBfMTI_8271761b-ad02-470e-bd17-8d4ebea99227">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6MjMxYWU4N2EyYzAwNDZmNGIyYTUwOTI1N2Y0OTYzN2YvdGFibGVyYW5nZToyMzFhZTg3YTJjMDA0NmY0YjJhNTA5MjU3ZjQ5NjM3Zl8zLTItMS0xLTQyMzgzL3RleHRyZWdpb246NjA1NGFiNTdiYmIxNGRhOTgwZDFjYjMxNmY0ZTkxZDBfMTY_24d02c6e-36b9-48a3-ae2c-f608ad52baa8">NY</ix:nonNumeric> <ix:nonNumeric contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6MjMxYWU4N2EyYzAwNDZmNGIyYTUwOTI1N2Y0OTYzN2YvdGFibGVyYW5nZToyMzFhZTg3YTJjMDA0NmY0YjJhNTA5MjU3ZjQ5NjM3Zl8zLTItMS0xLTQyMzgzL3RleHRyZWdpb246NjA1NGFiNTdiYmIxNGRhOTgwZDFjYjMxNmY0ZTkxZDBfMTk_157a0342-f550-40a0-88e9-5ad2895d46c6">10036</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices) (Zip Code)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6MjMxYWU4N2EyYzAwNDZmNGIyYTUwOTI1N2Y0OTYzN2YvdGFibGVyYW5nZToyMzFhZTg3YTJjMDA0NmY0YjJhNTA5MjU3ZjQ5NjM3Zl82LTAtMS0xLTQyMzgzL3RleHRyZWdpb246YTJhMTU1YWU3ZjMwNDg1NDkwMjY2MWFlYTk3Mzc2OWJfNTY_6b862cc0-1603-4f85-8a45-d6be14cfb946">(646)</ix:nonNumeric>&#160;<ix:nonNumeric contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6MjMxYWU4N2EyYzAwNDZmNGIyYTUwOTI1N2Y0OTYzN2YvdGFibGVyYW5nZToyMzFhZTg3YTJjMDA0NmY0YjJhNTA5MjU3ZjQ5NjM3Zl82LTAtMS0xLTQyMzgzL3RleHRyZWdpb246YTJhMTU1YWU3ZjMwNDg1NDkwMjY2MWFlYTk3Mzc2OWJfNTk_7f3f953c-2e59-4e73-8820-25bde1adcbac">200-5278</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGV4dHJlZ2lvbjo4Zjk3MDk4MGE0MTU0NzlmYTQ3M2YzOWIxM2JhNzgxMF8yODE0_215cf5de-00ad-40ad-aebe-db6d9fe17098">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR&#160;230.425) </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGV4dHJlZ2lvbjo4Zjk3MDk4MGE0MTU0NzlmYTQ3M2YzOWIxM2JhNzgxMF8yODE5_988005bb-e0b0-461e-afdc-02f02465b7e8">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR&#160;240.14a-12) </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGV4dHJlZ2lvbjo4Zjk3MDk4MGE0MTU0NzlmYTQ3M2YzOWIxM2JhNzgxMF8yODE1_4d729a1b-6fc9-4a12-95fc-9df7174a75c5">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR&#160;240.14d-2(b)) </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGV4dHJlZ2lvbjo4Zjk3MDk4MGE0MTU0NzlmYTQ3M2YzOWIxM2JhNzgxMF8yODIx_13e50984-7d09-480b-a00f-8bd10d7f8884">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR&#160;240.13e-4(c)) </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6NDc4NTMzZDNlYjg5NDNjZmI3ZDJmZmIyOGY1MWNlMjQvdGFibGVyYW5nZTo0Nzg1MzNkM2ViODk0M2NmYjdkMmZmYjI4ZjUxY2UyNF8xLTAtMS0xLTQyMzgz_86e014ba-1c58-4948-b244-065610b0db63">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6NDc4NTMzZDNlYjg5NDNjZmI3ZDJmZmIyOGY1MWNlMjQvdGFibGVyYW5nZTo0Nzg1MzNkM2ViODk0M2NmYjdkMmZmYjI4ZjUxY2UyNF8xLTEtMS0xLTQyMzgz_ffceceea-1f87-42eb-96c6-473c3b2766a5">SLS</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6NDc4NTMzZDNlYjg5NDNjZmI3ZDJmZmIyOGY1MWNlMjQvdGFibGVyYW5nZTo0Nzg1MzNkM2ViODk0M2NmYjdkMmZmYjI4ZjUxY2UyNF8xLTItMS0xLTQyMzgz_c0e805c3-fdf8-4e21-b6ff-4e935641c50b">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter). </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGV4dHJlZ2lvbjo4Zjk3MDk4MGE0MTU0NzlmYTQ3M2YzOWIxM2JhNzgxMF8yODIy_166c1956-aa95-48cc-a34e-86e55e4ed3da">&#9744;</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#9744; </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02. Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 11, 2022, SELLAS Life Sciences Group, Inc. (&#8220;SELLAS&#8221;) issued a press release (the &#8220;Press Release&#8221;) announcing its financial results for the quarter ended June 30, 2022 and providing a corporate update.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form&#160;8-K&#160;shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this Current Report on Form&#160;8-K shall not be incorporated by reference into any filing with the SEC made by SELLAS whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sls-202208118xkexhibit991.htm">Press Release dated August 11, 2022</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:6.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.146%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SELLAS Life Sciences Group, Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Barbara A. Wood</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barbara A. Wood</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Helvetica',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, General Counsel and Corporate Secretary</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>sls-202208118xkexhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4a1499ea5f2046b19a69d7b77910930b_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:16pt;font-weight:700;line-height:112%">SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2022 Financial Results </font></div><div><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">&#8211;  Reported Encouraging Updated Data in Q2 from Two Clinical Trials of Galinpepimut-S (GPS) in Combination with Checkpoint Inhibitors  &#8211;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8211; Provides Clinical Update for GFH009 Program  &#8211;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8211;  Cash Position of $27.0 million as of June 30, 2022  &#8211;</font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8211;  To Host Virtual Investor Symposium on GPS on September 15, 2022  &#8211; </font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NEW YORK, August 11, 2022 &#8211; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SELLAS Life Sciences Group, Inc.</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(NASDAQ&#58; SLS) (&#8220;SELLAS&#8217;&#8217; or the &#8220;Company&#8221;), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications,</font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">today provided a business update and reported its financial results for the quarter ended June 30, 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;During the second quarter of 2022, SELLAS continued to progress our pipeline of treatment options to potentially improve and prolong the lives of patients battling cancer, with our lead asset, GPS, achieving several important milestones,&#8221; said Angelos Stergiou, M.D., Sc.D. h.c., President and Chief Executive Officer of SELLAS. &#8220;We reported clinical benefits seen in preliminary data from our Phase 1&#47;2 clinical trial of GPS in combination with the checkpoint inhibitor KEYTRUDA&#174; in patients battling WT1+ advanced ovarian cancer as well as encouraging updated clinical data from a Phase 1 investigator-sponsored clinical trial of GPS in combination with another checkpoint inhibitor, OPDIVO&#174;, in patients with malignant pleural mesothelioma (MPM). In our Phase 3 REGAL study, we continued enrolling patients and activating additional sites across the United States, Europe, and Asia.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;Additionally, we were pleased to report encouraging preliminary results for our GFH009 program, a novel and highly selective, potentially first and best in class CDK9 inhibitor. Clinical data from the ongoing Phase 1 dose-escalating clinical trial of GFH009 in the United States and China in advanced relapsed and refractory lymphoma and acute myeloid leukemia (AML) shows no dose-limiting toxicities at all dose levels studied to date, while also demonstrating early indications of biological efficacy in assessable patients at multiple dose levels. We are excited by these preliminary results as well as the data from preclinical in vitro studies showing significant inhibition of cancer cell growth in four cell lines announced earlier this week, and we look forward to continuing to study GFH009 to further explore its anticancer effects,&#8221; concluded Dr. Stergiou.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Pipeline Updates&#58;</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">Galinpepimut-S (GPS)&#58; Wilms Tumor-1 (WT1) targeting peptide immunotherapeutic</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Phase 1&#47;2 Study in Combination with KEYTRUDA (pembrolizumab)&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In May 2022, SELLAS announced top-line clinical data showing clinical benefit from its Phase 1&#47;2 trial of GPS in combination with Merck&#8217;s anti-PD-1 therapy, KEYTRUDA, in patients diagnosed with WT1+ relapsed or refractory platinum resistant advanced metastatic ovarian cancer.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Phase 1 Study in Combination with OPDIVO (nivolumab)&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> In June 2022, SELLAS announced encouraging updated clinical data from a Phase 1 investigator-sponsored clinical trial of GPS in combination with the checkpoint inhibitor OPDIVO in patients with MPM who were either refractory to or relapsed after at least one line of the standard of care therapy.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Phase 3 REGAL Study&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> During the second quarter of 2022, SELLAS continued enrolling patients and activated additional sites in Poland, Greece and Hungary for its registrational global Phase 3 REGAL clinical trial in patients with AML. Enrollment for the study is scheduled to be completed in early in 2023, with an interim analysis planned to occur by the end of the first half of 2023. This timeline is based on current assumptions related to COVID-19 and its impact on the operations of clinical sites, as well as the duration of the pandemic. Because the interim analysis is event driven, it may become available at a different time than currently expected. The Company plans to activate additional sites in the United States and several countries in Europe and Asia throughout the remainder of 2022, including Serbia, Spain, Italy, Poland, Turkey and Taiwan. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">GFH009&#58; small molecule, highly selective CDK9 inhibitor</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Preclinical In Vitro Studies in Solid Cancer and AML Cell Lines</font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In early August, the Company announced results from its preclinical in vitro studies in solid cancer and AML cell lines. The data shows that GFH009 demonstrated significant anti-tumor effects in all four selected cell lines with cancer cell growth inhibited by 90 to 100 percent in three out of the four cell lines and by more than 50 percent in the fourth cell line.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Clinical Update on Phase 1 Trial&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of August 1, 2022, enrollment at all originally planned dose levels, administered twice a week, in the AML group (30 mg) and at the 22.5 mg dose level for the lymphoma group was completed. Among the 30 patients evaluable for safety and efficacy, no dose limiting toxicities have been observed. Four lymphoma patients (three at 4.5 mg and one at 9 mg) achieved stable disease (SD). One patient with peripheral T cell lymphoma treated at the 9 mg dose had 62% decrease in sum of the product of the perpendicular diameters for multiple lesions (SPD) based on computed tomography (CT). Two AML patients, one treated at the 9 mg dose level and one treated at the 15 mg dose level, had decreases of bone marrow blasts equal to or greater than 50%.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Phase 1 Clinical Trial Protocol Amendment&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> The Company announced in July that a second, once-a-week dose cohort has been added in its ongoing Phase 1 clinical trial in both the United States and China to study once-a-week administration starting at the higher dose level of 30 mg which will provide additional data for the safety and efficacy profile for GFH009.</font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Corporate Updates&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Underwritten Public Offering&#58;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> On April 5, 2022, the Company closed an underwritten public offering providing gross proceeds of $25.0 million, before deducting underwriting discounts and commissions and offering expenses.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Milestone Payment&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company received a $1.0 million milestone payment in May 2022 for the approval by China&#8217;s National Medical Products Administration (NMPA) of an IND application to initiate the first clinical trial in China for GPS. </font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Results for the Second Quarter 2022&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Licensing revenue&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There was no licensing revenue for the second quarter of 2022 and $1.0 million for the first half of 2022, which related to China&#8217;s NMPA approval of an IND application by 3D Medicines. This compares to $1.9 million for the second quarter of 2021 and $7.6 million for the first half of 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">R&#38;D Expenses&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development expenses for the second quarter of 2022 were $5.5 million, compared to $3.5 million for the same period in 2021. Research and development expenses were $10.1 million for the first half of 2022, compared to $7.7 million for the same period in 2021. The increase was primarily due to an increase in clinical trial expenses related to the Company&#8217;s ongoing Phase 3 REGAL clinical trial of GPS in AML patients, a ramp up of the manufacture of clinical trial materials and registration batches of GPS, and personnel related expenses due to increased headcount. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Acquired In-Process Research and Development&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There was no acquired in-process research and development for the second quarter of 2022. Acquired in-process research and development was $10.0 million for the first half of 2022, resulting from the in-licensing of GFH009. There was no acquired in-process research and development during the same periods in 2021.</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">G&#38;A Expenses&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative expenses for the second quarter of 2022 were $3.1 million, as compared to $2.8 million for the same period in 2021. The increase was primarily due to personnel related expenses due to increased headcount. General and administrative expenses were $6.1 million for the first half of 2022, compared to $6.4 million for the same period in 2021. The decrease was primarily due to a decrease in amortization expense associated with the capitalized contract acquisition costs of the 3D Medicines license agreement and a decrease in professional service fees, partially offset by an increase in personnel related expenses due to increased headcount.</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net Loss&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss was $8.4 million for the second quarter of 2022, or a basic and diluted loss per share of $0.41, compared to a net loss of $4.6 million for the same period in 2021, or a basic and diluted loss per share of $0.30. Net loss was $25.2 million for the first half of 2022, or a basic and diluted loss per share of $1.39, compared to a net loss of $7.0 million for the same period in 2021, or a basic and diluted loss per share of $0.47.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash Position&#58; </font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of June 30, 2022, cash and cash equivalents totaled approximately $27.0 million.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Upcoming Investor Symposium</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company will host a virtual investor symposium on Thursday, September 15, 2022, from 1&#58;00 p.m. to 2&#58;00 p.m. ET. The event will focus on the Company&#8217;s lead clinical asset, GPS, including the potential commercial opportunity for GPS in AML patients.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:17.901%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.899%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:110%">Event&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Galinpepimut-S Update Call</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:110%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Thursday, September 15, 2022</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:110%">Time&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">1&#58;00 p.m. Eastern Time</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:110%">Live Call&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">+1-877-407-9716 (U.S. Toll Free) or +1-201-493-6779 (International)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:110%">Webcast&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:110%">https&#58;&#47;&#47;viavid.webcasts.com&#47;starthere.jsp&#63;ei&#61;1550371&#38;tp_key&#61;70b7ae2fef</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For interested individuals unable to join the conference call, a replay will be available through September 29, 2022, at +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International). Participants must use the following code to access the replay of the call&#58; 13730135. An archived version of the webcast will also be available on SELLAS&#8217; Investor Relations site&#58; </font><font style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">https&#58;&#47;&#47;www.sellaslifesciences.com&#47;investors&#47;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About SELLAS Life Sciences Group, Inc.</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">  SELLAS Life Sciences Group, Inc. (NASDAQ&#58; SLS) is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS&#8217; lead product candidate, galinpepimut-S (GPS), is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other therapies to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is also developing GFH009, a small molecule, highly selective CDK9 inhibitor, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For more information on SELLAS, please visit </font><font style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">www.sellaslifesciences.com</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%">KEYTRUDA</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is a registered trademark of Merck Sharp &#38; Dohme Corp., a subsidiary of Merck &#38; Co., Inc., Kenilworth, N.J., USA, and is not a trademark of SELLAS. OPDIVO</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> is a registered trademark of Bristol Myers Squibb, and is not a trademark of SELLAS. The manufacturers of these brands are not affiliated with and do not endorse SELLAS or its products.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:110%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:110%">This press release contains forward-looking statements. All statements other than statements of historical facts are &#8220;forward-looking statements,&#8221; including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;intend,&#8221; or &#8220;continue&#8221; and other words or terms of similar meaning. These statements include, without limitation, statements related to the clinical development of GPS and GFH009 for various cancer indications, including the timing of commencement and completion of, and data from, clinical trials therefor, the potential for GPS and GFH009 as drug development candidates for various cancer indications, alone and in combination with other therapeutic agents and the timing for the completion of enrollment for the GPS REGAL Phase 3 </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:110%">clinical trial. These forward-looking statements are based on current plans, objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the COVID-19 pandemic and its impact on the Company&#8217;s clinical plans, risks and uncertainties associated with oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption &#8220;Risk Factors&#8221; in SELLAS&#8217; Annual Report on Form 10-K filed on March 31, 2022 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS&#8217; forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Investor Contact</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Allison Soss</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">KCSA Strategic Communications</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Email&#58; </font><font style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">SELLAS&#64;kcsa.com</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Phone&#58; 212.896.1267</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Media Contact</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Raquel Cona &#47; Michaela Fawcett</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">KCSA Strategic Communications</font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Email&#58; </font><font style="color:#0000ff;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">SELLAS&#64;kcsa.com</font><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Phone&#58; 212.896.1276</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share data)</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.573%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licensing revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,900&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,600&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of licensing revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,529&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,456&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,140&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,740&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,094&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,797&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,118&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,358&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,623&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,353&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,358&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,298&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,623)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,453)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25,358)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,698)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-operating income (expense), net&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(134)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(263)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total non-operating income (expense), net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(160)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(318)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,414)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,613)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25,158)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,016)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Per share information&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per common share, basic and diluted</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.41)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.30)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.39)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.47)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,286,624&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,270,288&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,104,176&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,074,887&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:115%">SELLAS LIFE SCIENCES GROUP, INC.</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Amounts in thousands, except share and per share data)</font></div><div style="text-align:center"><font style="color:#00497f;font-family:'Helvetica',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.766%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 30, 2022</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2021</font></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,987&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,355&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,650&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,589&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,737&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,044&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,045&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">723&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,914&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,914&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deposits and other assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">594&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,210&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,275&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,339&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,144&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,006&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,640&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development payable</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,500&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,186&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,982&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">783&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">610&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrant liability</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,153&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,928&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 7)</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $0.0001 par value&#59; 5,000,000 shares authorized&#59; Series A convertible preferred stock, 17,500 shares designated&#59; no shares issued and outstanding at June 30, 2022 and December 31, 2021</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Common stock, $0.0001 par value&#59; 350,000,000 shares authorized, 20,551,918 and 15,895,637 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,816&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158,948&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(163,761)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(138,603)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,057&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,347&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36.25pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,210&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Helvetica',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,275&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>sls-20220811.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:639b7971-57df-4e97-8611-e0137314c59d,g:c9bd04e0-8b28-4fc7-bb83-d7660659717a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sls="http://www.sellaslifesciences.com/20220811" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sellaslifesciences.com/20220811">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sls-20220811_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sls-20220811_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.sellaslifesciences.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>sls-20220811_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:639b7971-57df-4e97-8611-e0137314c59d,g:c9bd04e0-8b28-4fc7-bb83-d7660659717a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_aa7d5225-84bb-4f44-bd9e-5f902ac3bf90_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_a2e17945-0a2a-41c0-9132-b6428697013d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f95c1988-53a1-43fe-92bd-588025dc017a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_5de0ffdc-b445-44c3-9477-72eb05cc584e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_42ce979c-59fc-4af7-bc75-e7283e48494d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_2c5f9295-223a-471d-a082-692df31981f6_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_09c81748-06dd-4521-8b2a-2a50be90e554_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_70d1b7e1-936d-4571-bd0c-834dba75183b_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_dcac237d-3efb-406e-8cb6-1be726388c22_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7d99b116-4f97-4d6b-b90e-7515367c4891_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_749d1800-727a-47c7-b57a-06a2098d4171_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_ad787975-2d25-45bb-a59e-35efb650c0a6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_2f10799b-1078-4140-8c0b-fd062794d9b0_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f13c9cd4-38e8-4ffb-9799-6171bbf465bd_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_471bd602-c8ca-4b0d-9f9f-682a093ef6b5_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_df0ad12b-08aa-4250-8203-cd7ceac1cd13_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_803a4f84-2126-44a0-9299-f13ccd14d547_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_575e4e54-f1e1-4567-8475-4beb2c990859_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8dc916ee-6787-4e93-9b9c-cc8558620474_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8ebf0785-253e-4600-bc7f-6050b6ec9a65_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f8daedb3-b76a-40b7-b3ea-7ac7b62203e5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9825f520-766b-4ef3-a552-102c900bb8a6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_13fba785-c515-4e62-884a-780d2e9f505b_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>sls-20220811_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:639b7971-57df-4e97-8611-e0137314c59d,g:c9bd04e0-8b28-4fc7-bb83-d7660659717a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sellaslifesciences.com/role/Cover" xlink:type="simple" xlink:href="sls-20220811.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.sellaslifesciences.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c0077078-9537-4aad-b8a1-3a91fc3f6ee1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:to="loc_dei_DocumentType_c0077078-9537-4aad-b8a1-3a91fc3f6ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_bbda7067-78e5-4c1d-8161-6a829386b105" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:to="loc_dei_DocumentPeriodEndDate_bbda7067-78e5-4c1d-8161-6a829386b105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_675c8407-64ef-4d38-b376-8227a9488025" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:to="loc_dei_EntityRegistrantName_675c8407-64ef-4d38-b376-8227a9488025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_d3f68231-9c93-4230-b982-f7658d4efce5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:to="loc_dei_EntityIncorporationStateCountryCode_d3f68231-9c93-4230-b982-f7658d4efce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_ef1ec915-ee1b-4ded-a235-607c233fe743" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:to="loc_dei_EntityFileNumber_ef1ec915-ee1b-4ded-a235-607c233fe743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ff57009d-b9b3-42c9-a71c-17562acf419f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:to="loc_dei_EntityTaxIdentificationNumber_ff57009d-b9b3-42c9-a71c-17562acf419f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_400f7128-ed21-451d-aace-42697a7d02b3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:to="loc_dei_EntityAddressAddressLine1_400f7128-ed21-451d-aace-42697a7d02b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_9d8f6ad7-dc81-4117-9f8d-39efdf336bc8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:to="loc_dei_EntityAddressAddressLine2_9d8f6ad7-dc81-4117-9f8d-39efdf336bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_822bf29a-ba60-4dd1-865d-230adaf8d14b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:to="loc_dei_EntityAddressCityOrTown_822bf29a-ba60-4dd1-865d-230adaf8d14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_9ecdcf5d-f6e8-41e9-964e-063d60d96fba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:to="loc_dei_EntityAddressStateOrProvince_9ecdcf5d-f6e8-41e9-964e-063d60d96fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_11d95927-2c77-4822-be09-209542867172" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:to="loc_dei_EntityAddressPostalZipCode_11d95927-2c77-4822-be09-209542867172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9f127ed3-1b91-4519-b445-a9c371bf2ef1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:to="loc_dei_CityAreaCode_9f127ed3-1b91-4519-b445-a9c371bf2ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ddae6391-b558-4db9-b5dc-c214a9c266a5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:to="loc_dei_LocalPhoneNumber_ddae6391-b558-4db9-b5dc-c214a9c266a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_838afade-db36-467f-9c62-f8292c2c8f6a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:to="loc_dei_WrittenCommunications_838afade-db36-467f-9c62-f8292c2c8f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_9ac209ce-5646-4f12-80f9-e81f01072855" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:to="loc_dei_SolicitingMaterial_9ac209ce-5646-4f12-80f9-e81f01072855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_44b34f14-4167-45a4-b5eb-ba3a0a29d287" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:to="loc_dei_PreCommencementTenderOffer_44b34f14-4167-45a4-b5eb-ba3a0a29d287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_dfcdd3ad-c896-4a9d-9a6c-bd0890e8d6ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_dfcdd3ad-c896-4a9d-9a6c-bd0890e8d6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d2858577-f7dc-45f3-aa46-09d7943221de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:to="loc_dei_Security12bTitle_d2858577-f7dc-45f3-aa46-09d7943221de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b7de91f6-8df1-48ee-bef8-aa0b1cb7d10c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:to="loc_dei_TradingSymbol_b7de91f6-8df1-48ee-bef8-aa0b1cb7d10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_004027cb-877a-4a1b-9bfe-20ec9542a0b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:to="loc_dei_SecurityExchangeName_004027cb-877a-4a1b-9bfe-20ec9542a0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_333e757f-2e6f-4cd1-9847-740e9e841152" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:to="loc_dei_EntityEmergingGrowthCompany_333e757f-2e6f-4cd1-9847-740e9e841152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_8175847b-b2ab-4df4-9bf6-715db8a6db13" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:to="loc_dei_EntityCentralIndexKey_8175847b-b2ab-4df4-9bf6-715db8a6db13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f4ce68a8-dc7e-40eb-af83-47da7ac55749" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_30fbf460-4d6b-4126-a532-837d95e4d2be" xlink:to="loc_dei_AmendmentFlag_f4ce68a8-dc7e-40eb-af83-47da7ac55749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140473218489040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 11, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 11,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SELLAS Life Sciences Group, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-8099512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7 Times Square<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 2503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(646)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">200-5278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SLS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001390478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>sls-20220811_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sls-20220811.xsd" xlink:type="simple"/>
    <context id="i166be22d655e48bdad1472757bee2d71_D20220811-20220811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001390478</identifier>
        </entity>
        <period>
            <startDate>2022-08-11</startDate>
            <endDate>2022-08-11</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV80L2ZyYWc6NzU4ZGY2YzAyYWNmNDY4NjkzY2Y5NDFlMzE4MWJiMmQvdGFibGU6MDI2NzE3NGYyMDdkNDU3MmE0MjZhOTRmMzEwZjQxYjYvdGFibGVyYW5nZTowMjY3MTc0ZjIwN2Q0NTcyYTQyNmE5NGYzMTBmNDFiNl8xLTEtMS0xLTQyMzgz_6ce6e8c7-dc6d-4fc1-a7df-9717be746850">0001390478</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV80L2ZyYWc6NzU4ZGY2YzAyYWNmNDY4NjkzY2Y5NDFlMzE4MWJiMmQvdGFibGU6MDI2NzE3NGYyMDdkNDU3MmE0MjZhOTRmMzEwZjQxYjYvdGFibGVyYW5nZTowMjY3MTc0ZjIwN2Q0NTcyYTQyNmE5NGYzMTBmNDFiNl8yLTEtMS0xLTQyMzgz_75df2606-4940-48cf-af78-fc89eb45aca5">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGV4dHJlZ2lvbjo4Zjk3MDk4MGE0MTU0NzlmYTQ3M2YzOWIxM2JhNzgxMF8yODE3_78016580-b4c1-4b30-b874-40da58f7b07e">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGV4dHJlZ2lvbjo4Zjk3MDk4MGE0MTU0NzlmYTQ3M2YzOWIxM2JhNzgxMF8yMzQ_fe947ced-8c86-4f48-8a07-883ffca45ec8">2022-08-11</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGV4dHJlZ2lvbjo4Zjk3MDk4MGE0MTU0NzlmYTQ3M2YzOWIxM2JhNzgxMF8yODEy_3692c0bb-1032-4dfd-9304-ad1c1050c9ba">SELLAS Life Sciences Group, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6MjMxYWU4N2EyYzAwNDZmNGIyYTUwOTI1N2Y0OTYzN2YvdGFibGVyYW5nZToyMzFhZTg3YTJjMDA0NmY0YjJhNTA5MjU3ZjQ5NjM3Zl8wLTAtMS0xLTQyMzgz_e2ee1c96-bfbb-4613-9cd5-f400c8247d3d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6MjMxYWU4N2EyYzAwNDZmNGIyYTUwOTI1N2Y0OTYzN2YvdGFibGVyYW5nZToyMzFhZTg3YTJjMDA0NmY0YjJhNTA5MjU3ZjQ5NjM3Zl8wLTItMS0xLTQyMzgz_1562a388-d3eb-4613-bd84-05885c042741">001-33958</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6MjMxYWU4N2EyYzAwNDZmNGIyYTUwOTI1N2Y0OTYzN2YvdGFibGVyYW5nZToyMzFhZTg3YTJjMDA0NmY0YjJhNTA5MjU3ZjQ5NjM3Zl8wLTQtMS0xLTQyMzgz_9d00745a-2f0e-442c-8927-ac1b3a165101">20-8099512</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6MjMxYWU4N2EyYzAwNDZmNGIyYTUwOTI1N2Y0OTYzN2YvdGFibGVyYW5nZToyMzFhZTg3YTJjMDA0NmY0YjJhNTA5MjU3ZjQ5NjM3Zl8zLTItMS0xLTQyMzgzL3RleHRyZWdpb246NjA1NGFiNTdiYmIxNGRhOTgwZDFjYjMxNmY0ZTkxZDBfNQ_1d958634-68dd-4059-a0d4-44856569ee4f">7 Times Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6MjMxYWU4N2EyYzAwNDZmNGIyYTUwOTI1N2Y0OTYzN2YvdGFibGVyYW5nZToyMzFhZTg3YTJjMDA0NmY0YjJhNTA5MjU3ZjQ5NjM3Zl8zLTItMS0xLTQyMzgzL3RleHRyZWdpb246NjA1NGFiNTdiYmIxNGRhOTgwZDFjYjMxNmY0ZTkxZDBfOQ_5d88de44-e2f8-43f8-a38a-1a26a5b8c1ba">Suite 2503</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6MjMxYWU4N2EyYzAwNDZmNGIyYTUwOTI1N2Y0OTYzN2YvdGFibGVyYW5nZToyMzFhZTg3YTJjMDA0NmY0YjJhNTA5MjU3ZjQ5NjM3Zl8zLTItMS0xLTQyMzgzL3RleHRyZWdpb246NjA1NGFiNTdiYmIxNGRhOTgwZDFjYjMxNmY0ZTkxZDBfMTI_8271761b-ad02-470e-bd17-8d4ebea99227">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6MjMxYWU4N2EyYzAwNDZmNGIyYTUwOTI1N2Y0OTYzN2YvdGFibGVyYW5nZToyMzFhZTg3YTJjMDA0NmY0YjJhNTA5MjU3ZjQ5NjM3Zl8zLTItMS0xLTQyMzgzL3RleHRyZWdpb246NjA1NGFiNTdiYmIxNGRhOTgwZDFjYjMxNmY0ZTkxZDBfMTY_24d02c6e-36b9-48a3-ae2c-f608ad52baa8">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6MjMxYWU4N2EyYzAwNDZmNGIyYTUwOTI1N2Y0OTYzN2YvdGFibGVyYW5nZToyMzFhZTg3YTJjMDA0NmY0YjJhNTA5MjU3ZjQ5NjM3Zl8zLTItMS0xLTQyMzgzL3RleHRyZWdpb246NjA1NGFiNTdiYmIxNGRhOTgwZDFjYjMxNmY0ZTkxZDBfMTk_157a0342-f550-40a0-88e9-5ad2895d46c6">10036</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6MjMxYWU4N2EyYzAwNDZmNGIyYTUwOTI1N2Y0OTYzN2YvdGFibGVyYW5nZToyMzFhZTg3YTJjMDA0NmY0YjJhNTA5MjU3ZjQ5NjM3Zl82LTAtMS0xLTQyMzgzL3RleHRyZWdpb246YTJhMTU1YWU3ZjMwNDg1NDkwMjY2MWFlYTk3Mzc2OWJfNTY_6b862cc0-1603-4f85-8a45-d6be14cfb946">(646)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6MjMxYWU4N2EyYzAwNDZmNGIyYTUwOTI1N2Y0OTYzN2YvdGFibGVyYW5nZToyMzFhZTg3YTJjMDA0NmY0YjJhNTA5MjU3ZjQ5NjM3Zl82LTAtMS0xLTQyMzgzL3RleHRyZWdpb246YTJhMTU1YWU3ZjMwNDg1NDkwMjY2MWFlYTk3Mzc2OWJfNTk_7f3f953c-2e59-4e73-8820-25bde1adcbac">200-5278</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGV4dHJlZ2lvbjo4Zjk3MDk4MGE0MTU0NzlmYTQ3M2YzOWIxM2JhNzgxMF8yODE0_215cf5de-00ad-40ad-aebe-db6d9fe17098">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGV4dHJlZ2lvbjo4Zjk3MDk4MGE0MTU0NzlmYTQ3M2YzOWIxM2JhNzgxMF8yODE5_988005bb-e0b0-461e-afdc-02f02465b7e8">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGV4dHJlZ2lvbjo4Zjk3MDk4MGE0MTU0NzlmYTQ3M2YzOWIxM2JhNzgxMF8yODE1_4d729a1b-6fc9-4a12-95fc-9df7174a75c5">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGV4dHJlZ2lvbjo4Zjk3MDk4MGE0MTU0NzlmYTQ3M2YzOWIxM2JhNzgxMF8yODIx_13e50984-7d09-480b-a00f-8bd10d7f8884">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6NDc4NTMzZDNlYjg5NDNjZmI3ZDJmZmIyOGY1MWNlMjQvdGFibGVyYW5nZTo0Nzg1MzNkM2ViODk0M2NmYjdkMmZmYjI4ZjUxY2UyNF8xLTAtMS0xLTQyMzgz_86e014ba-1c58-4948-b244-065610b0db63">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6NDc4NTMzZDNlYjg5NDNjZmI3ZDJmZmIyOGY1MWNlMjQvdGFibGVyYW5nZTo0Nzg1MzNkM2ViODk0M2NmYjdkMmZmYjI4ZjUxY2UyNF8xLTEtMS0xLTQyMzgz_ffceceea-1f87-42eb-96c6-473c3b2766a5">SLS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGFibGU6NDc4NTMzZDNlYjg5NDNjZmI3ZDJmZmIyOGY1MWNlMjQvdGFibGVyYW5nZTo0Nzg1MzNkM2ViODk0M2NmYjdkMmZmYjI4ZjUxY2UyNF8xLTItMS0xLTQyMzgz_c0e805c3-fdf8-4e21-b6ff-4e935641c50b">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i166be22d655e48bdad1472757bee2d71_D20220811-20220811"
      id="id3VybDovL2RvY3MudjEvZG9jOjU5N2NkNTMyZTc5NjRhN2I4Yjc3YjI0NDhjNGQ3N2ZlL3NlYzo1OTdjZDUzMmU3OTY0YTdiOGI3N2IyNDQ4YzRkNzdmZV8xL2ZyYWc6OGY5NzA5ODBhNDE1NDc5ZmE0NzNmMzliMTNiYTc4MTAvdGV4dHJlZ2lvbjo4Zjk3MDk4MGE0MTU0NzlmYTQ3M2YzOWIxM2JhNzgxMF8yODIy_166c1956-aa95-48cc-a34e-86e55e4ed3da">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M2F*>=D($MIH7'7J%>5I0E8$ M^HO6EC+)0Q-FN9R[VBFE@H76K+$H"91^7Z
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ VH$+5:K$(A8S 0  (@(   \
M  !X;"]W;W)K8F]O:RYX;6R-4=%NPC ,_)4J'[ 6M"$-45Y VY"F#8V)]]"Z
MU"*)*\>%C:^?VZH:TE[VE-S9NMQ=%A?BTX'HE'QY%V)N:I%FGJ:QJ,';>$<-
M!)U4Q-Z*0CZFL6&P9:P!Q+MTFF6SU%L,9KD8M;:<W@(2* 0I*-D1>X1+_)UW
M,#ECQ ,ZE._<]'<')O$8T.,5RMQD)HDU75Z(\4I!K-L53,[E9C(,]L""Q1]Z
MUYG\M(?8,V(/'U:-Y&:6J6"%'*7?Z/6M>CR#+@^H%7I")\!K*_#,U#88CIV,
MIDAO8O0]C.=0XIS_4R-5%1:PIJ+U$&3HD<%U!D.LL8DF"=9#;E9T!N[RZ .;
M<L@F:NJF*9ZC#GA3#O9&3R54&*!\4YFHO/93;#GICEYG>O\P>=0>6N=6RKV'
M5[+E&''\GN4/4$L#!!0    ( -J!"U4D'INBK0   /@!   :    >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S
M(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.
MXS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X\ \PO%WH
MJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W
M1:[-XPFNWPQP>'3^ 5!+ P04    " #:@0M599!YDAD!  #/ P  $P   %M#
M;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK
M_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBN
MM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-F<!B63R-
MPLQJ2AFC-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>
MI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!
M9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8
MYL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( -J!"U4'
M04UB@0   +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL
M4$L! A0#%     @ VH$+5:$FP0[N    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ VH$+59E<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " #:@0M5/]=;LF($   G$0  &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ VH$+59^@&_"Q @  X@P
M  T              ( !I0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #:
M@0M5EXJ[',     3 @  "P              @ &!#P  7W)E;',O+G)E;'-0
M2P$"% ,4    " #:@0M5JL0B%C,!   B @  #P              @ %J$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ VH$+520>FZ*M    ^ $  !H
M             ( !RA$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ VH$+5660>9(9 0  SP,  !,              ( !KQ(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ^1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="sls-20220811.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sellaslifesciences.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="sls-20220811.htm">sls-20220811.htm</File>
    <File>sls-20220811.xsd</File>
    <File>sls-202208118xkexhibit991.htm</File>
    <File>sls-20220811_lab.xml</File>
    <File>sls-20220811_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sls-20220811.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "sls-20220811.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sls-20220811_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sls-20220811_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sls-20220811.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "sls",
   "nsuri": "http://www.sellaslifesciences.com/20220811",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20220811.htm",
      "contextRef": "i166be22d655e48bdad1472757bee2d71_D20220811-20220811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.sellaslifesciences.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sls-20220811.htm",
      "contextRef": "i166be22d655e48bdad1472757bee2d71_D20220811-20220811",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sellaslifesciences.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0001390478-22-000021-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001390478-22-000021-xbrl.zip
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MMR9S#4T2S ,;NI9+?]</CKPNZQ,\"Q,@;/XHCV%+D;"D8#E;H')(!F=?"FR
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MLY+H"3#ZH%'^<O:=_?ORZQ\:Z\4W,>!/UQ.$S.+CJ>":HRO!M= *?PJ\V->
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M!R"!B *WH2[9991\O=!YD)A-LL?*QO,D?D;.-46%5U!]*2XTO1$6>&&C2BT
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M+2!$A8 3Q@##1D*J%(V)Z9H1H($&!/<\]WEFNF<$J$-&X$77K\P(=C%UD(P
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M;N>VNLXYYU%EN!IB4280/E P6BA0@D03M: TFZ/<^*SQ<6 LOMXX7=A%\'&
MDC6V/,04Y^J7>)UKJC)T&!-@9ON]'4GT@$M0- M.6QD<G>.)]R.SXYA8< ER
MNIBO3,,^YKNASWG?E_8T3\)'J:V&X%4$9->!39J#4,$JZ[-,"3.)@@?FQD5_
MP57(EXLW6]3?K)^(=X0']K9N3_0O_7\G]K;^ U!+ 0(4 Q0    ( -J!"U5E
MKKKT=Q4  +NA   0              "  0    !S;',M,C R,C X,3$N:'1M
M4$L! A0#%     @ VH$+52\Y3E%Q @  B0<  !               ( !I14
M '-L<RTR,#(R,#@Q,2YX<V102P$"% ,4    " #:@0M5=TSH83PD  "9C0$
M'0              @ %$&   <VQS+3(P,C(P.#$Q.'AK97AH:6)I=#DY,2YH
M=&U02P$"% ,4    " #:@0M55<Z[7I$*   180  %               @ &[
M/   <VQS+3(P,C(P.#$Q7VQA8BYX;6Q02P$"% ,4    " #:@0M5Z-C('-(&
M   ),P  %               @ %^1P  <VQS+3(P,C(P.#$Q7W!R92YX;6Q0
52P4&      4 !0!+ 0  @DX

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
